Connect Biopharma Holdings Limited – NASDAQ:CNTB

Add to watchlist

$1.81

+0.67

+58.77%

Market closed

Open in about 9 hours

-8.80%

month

-8.80%

quarter

+14.00%

year

Market Cap	58.56M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-1.39

Revenue	N/A
EBITDA	-34.38M
Income	-30.62M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Connect Biopharma Holdings Limited (NASDAQ:CNTB): Profit margin
Mar 2023	0	-15.43K
Jun 2023	0	-30.58M
Sep 2023	0	-15.22K
Dec 2023	0	-14.80K

Connect Biopharma Holdings Limited Financials Estimate

Q Y

Connect Biopharma Holdings Limited (NASDAQ:CNTB): Analyst Estimates
2025	251.98M	-432.42M	-171.6%
2026	203.90M	-560.40M	-274.83%
2027	333.32M	-133.96M	-40.19%
2028	400.94M	-116.56M	-29.07%

Analysts Price target
Financials & Ratios estimates

Connect Biopharma Holdings Limited (NASDAQ:CNTB): Debt to assets
Dec 2022	1211930000	115.06M	9.49%
Mar 2023	1041095	111.38K	10.7%
Jun 2023	1041095000	111.38M	10.7%
Dec 2023	125892000	24.84M	19.74%

Connect Biopharma Holdings Limited (NASDAQ:CNTB): Cash Flow
Mar 2023	-15.68K	17.28K	-65
Jun 2023	-31.08M	34.25M	-130.28K
Sep 2023	-9.2K	21.31K	-61
Dec 2023	-8.77K	20.83K	-59

Connect Biopharma Holdings Limited alternative data

Connect Biopharma Holdings Limited
Employees

Connect Biopharma Holdings Limited (NASDAQ:CNTB): Employee count
Aug 2023	100
Sep 2023	100
Oct 2023	100
Nov 2023	100
Dec 2023	100
Jan 2024	100
Feb 2024	100
Mar 2024	100
Apr 2024	100
May 2024	81
Jun 2024	81
Jul 2024	81

Connect Biopharma Holdings Limited
Hedge Funds Holdings Q1 2023

2.37% -18.77%

of CNTB is owned by hedge funds

6 -13

hedge funds hold CNTB stock

1.30M -10.33M

shares is hold by hedge funds

CNTB hedge funds holdings changes

Connect Biopharma Holdings Limited
Earnings Call Transcripts

Quarter	Transcript
Q2 2022 13 Sep 2022	Q2 2022 Earnings Call Transcript

CNTB earnings call transcripts

Connect Biopharma Holdings Limited
Latest News

Tuesday, 15 October 2024
07:30	Attovia Therapeutics Appoints Chief Financial Officer	globenewswire.com
Wednesday, 2 October 2024
16:14	CNTB Stock Surges Over 5% Amid Strong Financial Performance	gurufocus.com
Thursday, 5 September 2024
16:05	Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update	globenewswire.com
Monday, 1 July 2024
08:00	Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum	globenewswire.com
Wednesday, 12 June 2024
18:03	Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
16:15	Connect Biopharma Announces New Leadership and Chair of the Board of Directors	globenewswire.com
Wednesday, 22 May 2024
16:05	Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma	globenewswire.com
Tuesday, 7 May 2024
06:30	Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma	GlobeNewsWire
Tuesday, 19 March 2024
08:30	Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference	GlobeNewsWire
Monday, 11 December 2023
16:05	Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023	GlobeNewsWire
Tuesday, 28 November 2023
11:17	Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?	Zacks Investment Research
Monday, 20 November 2023
16:41	Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023	GlobeNewsWire
Monday, 6 November 2023
11:18	Is Connect Biopharma Holdings (CNTB) Outperforming Other Medical Stocks This Year?	Zacks Investment Research
Friday, 20 October 2023
11:18	Has Connect Biopharma Holdings (CNTB) Outpaced Other Medical Stocks This Year?	Zacks Investment Research
Friday, 15 September 2023
13:32	Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Upgraded to Buy: What Does It Mean for the Stock?	Zacks Investment Research
Thursday, 24 August 2023
18:21	Connect Biopharma to Participate in Upcoming September Investor Conferences	GlobeNewsWire
Monday, 20 March 2023
10:41	CNTB Stock Surges Over 20%: Explanation	Pulse2
Friday, 17 March 2023
16:38	Connect Biopharma stock up more than 40% after trial data	Market Watch
Monday, 6 February 2023
08:30	Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California	GlobeNewsWire
Monday, 19 December 2022
08:00	Connect Biopharma to Present at the San Francisco Biotech Showcase in January	GlobeNewsWire
Thursday, 27 October 2022
16:05	Connect Biopharma To Present at Upcoming Investor and Scientific Conferences	GlobeNewsWire
Monday, 3 October 2022
16:10	Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis	GlobeNewsWire
Monday, 26 September 2022
00:13	Connect Biopharma Is A Sleeper Heading Into October Data Readout	Seeking Alpha
Tuesday, 13 September 2022
20:51	Connect Biopharma Holdings Limited (CNTB) Q2 2022 Earnings Call Transcript	Seeking Alpha
Thursday, 1 September 2022
08:00	Connect Biopharma to Report First Half 2022 Financial Results on September 13	GlobeNewsWire
Wednesday, 29 June 2022
20:11	Hot Penny Stocks That Are Climbing Right Now	PennyStocks
Wednesday, 8 June 2022
13:33	All You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to Buy	Zacks Investment Research
Wednesday, 4 May 2022
07:54	Connect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage Study	Benzinga
Wednesday, 9 February 2022
07:00	Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference	GlobeNewsWire
Thursday, 13 January 2022
12:55	Connect Biopharma's Latest Dermatitis Drug Update Fails to Pump Up Shares	Benzinga

Frequently Asked Questions (FAQ)

What's the price of Connect Biopharma Holdings Limited stock today?

One share of Connect Biopharma Holdings Limited stock can currently be purchased for approximately $1.81.
When is Connect Biopharma Holdings Limited's next earnings date?

Unfortunately, Connect Biopharma Holdings Limited's (CNTB) next earnings date is currently unknown.
Does Connect Biopharma Holdings Limited pay dividends?

No, Connect Biopharma Holdings Limited does not pay dividends.
How much money does Connect Biopharma Holdings Limited make?

Connect Biopharma Holdings Limited has a market capitalization of 58.56M.
What is Connect Biopharma Holdings Limited's stock symbol?

Connect Biopharma Holdings Limited is traded on the NASDAQ under the ticker symbol "CNTB".
What is Connect Biopharma Holdings Limited's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Connect Biopharma Holdings Limited?

Shares of Connect Biopharma Holdings Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Connect Biopharma Holdings Limited have?

As Jul 2024, Connect Biopharma Holdings Limited employs 81 workers, which is 19% less then previous quarter.
When Connect Biopharma Holdings Limited went public?

Connect Biopharma Holdings Limited is publicly traded company for more then 4 years since IPO on 19 Mar 2021.
What is Connect Biopharma Holdings Limited's official website?

The official website for Connect Biopharma Holdings Limited is connectbiopharm.com.
How can i contact Connect Biopharma Holdings Limited?

Connect Biopharma Holdings Limited can be reached via phone at +86 512 5357 7866.

Connect Biopharma Holdings Limited

connectbiopharm.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

+86 512 5357 7866

East R&D Building
Taicang, 215400

CIK: 0001835268
ISIN: US2075231017
CUSIP: 207523101